 Jed Lampe
Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP3A | 15 | 2026 | 93 | 5.670 |
Why?
| | Cytochrome P-450 Enzyme System | 14 | 2026 | 162 | 5.000 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 5 | 2024 | 18 | 2.580 |
Why?
| | Pseudomonas aeruginosa | 3 | 2025 | 356 | 2.040 |
Why?
| | Fluorocarbons | 3 | 2026 | 143 | 1.580 |
Why?
| | Antiviral Agents | 4 | 2025 | 767 | 1.370 |
Why?
| | Hepatocytes | 4 | 2026 | 223 | 1.100 |
Why?
| | Dehydroepiandrosterone Sulfate | 3 | 2024 | 42 | 1.080 |
Why?
| | Tretinoin | 2 | 2026 | 124 | 1.070 |
Why?
| | Pharmaceutical Preparations | 4 | 2025 | 170 | 1.060 |
Why?
| | Retinoic Acid 4-Hydroxylase | 1 | 2026 | 3 | 0.960 |
Why?
| | Decanoic Acids | 1 | 2026 | 14 | 0.960 |
Why?
| | Teratogens | 1 | 2026 | 20 | 0.950 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2026 | 276 | 0.950 |
Why?
| | Carboxylesterase | 1 | 2025 | 4 | 0.930 |
Why?
| | Celecoxib | 1 | 2025 | 41 | 0.930 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2025 | 23 | 0.920 |
Why?
| | Prodrugs | 1 | 2025 | 52 | 0.880 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2025 | 194 | 0.880 |
Why?
| | Clobetasol | 1 | 2024 | 7 | 0.870 |
Why?
| | Adenosine Monophosphate | 1 | 2025 | 86 | 0.870 |
Why?
| | Raloxifene Hydrochloride | 1 | 2024 | 15 | 0.850 |
Why?
| | Alanine | 1 | 2025 | 171 | 0.850 |
Why?
| | Ciprofloxacin | 1 | 2024 | 26 | 0.850 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1087 | 0.830 |
Why?
| | Nevirapine | 1 | 2023 | 18 | 0.810 |
Why?
| | Organoids | 1 | 2025 | 141 | 0.810 |
Why?
| | Archaeal Proteins | 4 | 2015 | 49 | 0.770 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 257 | 0.770 |
Why?
| | Deuterium | 1 | 2023 | 100 | 0.770 |
Why?
| | Aloe | 1 | 2022 | 2 | 0.740 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2022 | 35 | 0.720 |
Why?
| | Quinolones | 1 | 2024 | 201 | 0.710 |
Why?
| | Fluoresceins | 1 | 2021 | 48 | 0.700 |
Why?
| | Aminophenols | 1 | 2024 | 201 | 0.700 |
Why?
| | Lopinavir | 1 | 2021 | 30 | 0.670 |
Why?
| | Ritonavir | 1 | 2021 | 75 | 0.650 |
Why?
| | Growth and Development | 1 | 2019 | 9 | 0.610 |
Why?
| | Xenobiotics | 1 | 2019 | 32 | 0.600 |
Why?
| | Lanthanoid Series Elements | 1 | 2019 | 2 | 0.600 |
Why?
| | Chelating Agents | 1 | 2019 | 71 | 0.570 |
Why?
| | Octamer Transcription Factor-1 | 1 | 2018 | 5 | 0.570 |
Why?
| | Anti-Retroviral Agents | 1 | 2021 | 250 | 0.570 |
Why?
| | Premature Birth | 1 | 2023 | 380 | 0.570 |
Why?
| | Disease | 1 | 2019 | 98 | 0.570 |
Why?
| | Biological Products | 1 | 2022 | 252 | 0.560 |
Why?
| | Microsomes, Liver | 3 | 2024 | 85 | 0.550 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 111 | 0.540 |
Why?
| | Molecular Docking Simulation | 3 | 2025 | 124 | 0.530 |
Why?
| | Sulfolobus acidocaldarius | 3 | 2015 | 4 | 0.510 |
Why?
| | Ligands | 6 | 2018 | 673 | 0.500 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2014 | 10 | 0.500 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1158 | 0.450 |
Why?
| | Cytochromes b5 | 1 | 2014 | 2 | 0.430 |
Why?
| | Organic Cation Transporter 1 | 1 | 2014 | 1 | 0.420 |
Why?
| | Testosterone | 2 | 2017 | 419 | 0.410 |
Why?
| | Heme | 3 | 2023 | 89 | 0.400 |
Why?
| | Iron | 3 | 2023 | 359 | 0.390 |
Why?
| | Methyltyrosines | 2 | 2010 | 3 | 0.370 |
Why?
| | Signal Transduction | 1 | 2026 | 5226 | 0.370 |
Why?
| | Humans | 25 | 2026 | 144759 | 0.360 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.350 |
Why?
| | Oxazines | 2 | 2008 | 37 | 0.340 |
Why?
| | Kinetics | 4 | 2022 | 1627 | 0.310 |
Why?
| | Models, Molecular | 5 | 2018 | 1618 | 0.280 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2010 | 630 | 0.270 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2023 | 139 | 0.260 |
Why?
| | Pregnancy | 3 | 2026 | 7190 | 0.250 |
Why?
| | Hydrolysis | 2 | 2025 | 199 | 0.250 |
Why?
| | Fetus | 2 | 2024 | 803 | 0.250 |
Why?
| | Protein Conformation | 4 | 2018 | 946 | 0.240 |
Why?
| | Infant, Newborn | 3 | 2026 | 6429 | 0.240 |
Why?
| | Hydroxylamines | 1 | 2025 | 8 | 0.230 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2025 | 23 | 0.230 |
Why?
| | Cytidine | 1 | 2025 | 9 | 0.230 |
Why?
| | Animals | 9 | 2026 | 38058 | 0.230 |
Why?
| | Amino Acids | 1 | 2008 | 521 | 0.210 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2024 | 45 | 0.210 |
Why?
| | Drug Discovery | 1 | 2025 | 155 | 0.210 |
Why?
| | Protein Binding | 5 | 2018 | 2273 | 0.210 |
Why?
| | Naphthalenes | 1 | 2024 | 56 | 0.210 |
Why?
| | Binding Sites | 5 | 2018 | 1329 | 0.210 |
Why?
| | Liver | 2 | 2023 | 1887 | 0.200 |
Why?
| | HEK293 Cells | 2 | 2018 | 744 | 0.200 |
Why?
| | HIV Reverse Transcriptase | 1 | 2023 | 31 | 0.200 |
Why?
| | Cells, Cultured | 2 | 2026 | 4154 | 0.200 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2023 | 87 | 0.200 |
Why?
| | Substrate Specificity | 2 | 2018 | 388 | 0.190 |
Why?
| | Maternal-Fetal Exchange | 1 | 2024 | 169 | 0.190 |
Why?
| | Cysteine | 3 | 2012 | 210 | 0.190 |
Why?
| | Cell Culture Techniques | 1 | 2025 | 375 | 0.190 |
Why?
| | Dehydroepiandrosterone | 1 | 2023 | 50 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2025 | 338 | 0.190 |
Why?
| | Hepacivirus | 1 | 2024 | 243 | 0.180 |
Why?
| | Cephalexin | 1 | 2022 | 14 | 0.180 |
Why?
| | Molecular Structure | 1 | 2023 | 499 | 0.180 |
Why?
| | Arachidonic Acid | 1 | 2022 | 101 | 0.180 |
Why?
| | Protease Inhibitors | 1 | 2022 | 102 | 0.170 |
Why?
| | Hepatitis C | 1 | 2024 | 254 | 0.170 |
Why?
| | Molecular Conformation | 1 | 2021 | 148 | 0.160 |
Why?
| | Fatty Acids | 2 | 2022 | 450 | 0.160 |
Why?
| | Base Sequence | 4 | 2019 | 2190 | 0.160 |
Why?
| | Vasodilator Agents | 1 | 2022 | 331 | 0.150 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 221 | 0.150 |
Why?
| | Drug Combinations | 1 | 2021 | 390 | 0.150 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 329 | 0.150 |
Why?
| | High-Throughput Screening Assays | 1 | 2021 | 175 | 0.150 |
Why?
| | Birth Weight | 1 | 2023 | 522 | 0.150 |
Why?
| | Water | 1 | 2023 | 469 | 0.150 |
Why?
| | Pentetic Acid | 1 | 2019 | 11 | 0.150 |
Why?
| | Click Chemistry | 1 | 2019 | 51 | 0.140 |
Why?
| | Spectrometry, Fluorescence | 3 | 2008 | 168 | 0.140 |
Why?
| | Copper | 1 | 2019 | 113 | 0.140 |
Why?
| | Cell Differentiation | 1 | 2026 | 2050 | 0.140 |
Why?
| | Burns | 1 | 2023 | 377 | 0.140 |
Why?
| | Principal Component Analysis | 1 | 2018 | 197 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 388 | 0.130 |
Why?
| | Hydroxylation | 1 | 2017 | 49 | 0.130 |
Why?
| | Biotransformation | 1 | 2017 | 63 | 0.130 |
Why?
| | Bacterial Proteins | 1 | 2024 | 955 | 0.130 |
Why?
| | Stereoisomerism | 1 | 2017 | 104 | 0.130 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1997 | 141 | 0.130 |
Why?
| | Allosteric Regulation | 2 | 2007 | 98 | 0.130 |
Why?
| | Protein Transport | 1 | 2018 | 441 | 0.120 |
Why?
| | Transcriptome | 1 | 2023 | 1045 | 0.120 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2016 | 15 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1907 | 0.120 |
Why?
| | Caprylates | 1 | 2016 | 27 | 0.120 |
Why?
| | Catalytic Domain | 3 | 2015 | 232 | 0.120 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 888 | 0.120 |
Why?
| | Alkanesulfonic Acids | 1 | 2016 | 49 | 0.120 |
Why?
| | HIV-1 | 1 | 2021 | 896 | 0.110 |
Why?
| | Crystallography, X-Ray | 3 | 2015 | 492 | 0.110 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2007 | 594 | 0.110 |
Why?
| | Gene Expression | 2 | 2016 | 1490 | 0.100 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2015 | 346 | 0.100 |
Why?
| | Neurotransmitter Agents | 1 | 2014 | 82 | 0.100 |
Why?
| | Serum Albumin | 1 | 2014 | 147 | 0.100 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2014 | 148 | 0.100 |
Why?
| | Norepinephrine | 1 | 2014 | 196 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.100 |
Why?
| | Protein Isoforms | 1 | 2014 | 402 | 0.100 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2012 | 21 | 0.090 |
Why?
| | Female | 4 | 2026 | 78271 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2014 | 356 | 0.090 |
Why?
| | Dopamine | 1 | 2014 | 283 | 0.090 |
Why?
| | Protein Folding | 1 | 2012 | 279 | 0.080 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2007 | 85 | 0.080 |
Why?
| | DNA | 1 | 1997 | 1463 | 0.080 |
Why?
| | Lauric Acids | 1 | 2010 | 9 | 0.080 |
Why?
| | Spectrophotometry | 1 | 2010 | 61 | 0.080 |
Why?
| | Erythromycin | 2 | 2006 | 20 | 0.080 |
Why?
| | Prospective Studies | 1 | 2022 | 7990 | 0.070 |
Why?
| | Catalysis | 1 | 2010 | 322 | 0.070 |
Why?
| | Acetaminophen | 1 | 2011 | 264 | 0.070 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2007 | 26 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2012 | 381 | 0.070 |
Why?
| | Bacteria | 2 | 2022 | 889 | 0.060 |
Why?
| | Male | 5 | 2025 | 72315 | 0.060 |
Why?
| | Naphthalenesulfonates | 1 | 2006 | 7 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2006 | 13 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4271 | 0.060 |
Why?
| | Photoaffinity Labels | 1 | 2005 | 6 | 0.060 |
Why?
| | Molecular Probe Techniques | 1 | 2005 | 8 | 0.060 |
Why?
| | HIV Infections | 1 | 2021 | 3154 | 0.060 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2007 | 319 | 0.060 |
Why?
| | Tryptophan | 1 | 2006 | 181 | 0.060 |
Why?
| | Quinolines | 1 | 2006 | 193 | 0.060 |
Why?
| | Models, Chemical | 1 | 2006 | 269 | 0.060 |
Why?
| | Barrett Esophagus | 1 | 2007 | 165 | 0.060 |
Why?
| | Progesterone | 1 | 2006 | 255 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2930 | 0.050 |
Why?
| | Esophageal Neoplasms | 1 | 2007 | 347 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2430 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 5 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 5 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Cefadroxil | 1 | 2022 | 8 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 22 | 0.050 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 369 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 862 | 0.040 |
Why?
| | Adult | 2 | 2023 | 40449 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 370 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2878 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 2832 | 0.040 |
Why?
| | Leishmania | 1 | 1999 | 3 | 0.040 |
Why?
| | RNA, Protozoan | 1 | 1999 | 60 | 0.040 |
Why?
| | Oligonucleotides, Antisense | 1 | 1999 | 116 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 4089 | 0.040 |
Why?
| | Berberine Alkaloids | 1 | 1997 | 1 | 0.030 |
Why?
| | Chlorambucil | 1 | 1997 | 10 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 455 | 0.030 |
Why?
| | Alkylation | 1 | 1997 | 27 | 0.030 |
Why?
| | Exons | 1 | 1999 | 358 | 0.030 |
Why?
| | Base Composition | 1 | 1997 | 82 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 1 | 1997 | 57 | 0.030 |
Why?
| | Guanosine | 1 | 1997 | 40 | 0.030 |
Why?
| | Guanine | 1 | 1997 | 87 | 0.030 |
Why?
| | HLA-DQ Antigens | 1 | 1997 | 173 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 1997 | 207 | 0.030 |
Why?
| | Time Factors | 1 | 2007 | 7173 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1782 | 0.030 |
Why?
| | Mice | 3 | 2023 | 18339 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 1999 | 458 | 0.030 |
Why?
| | Adenosine | 1 | 1997 | 255 | 0.030 |
Why?
| | Nucleic Acid Conformation | 1 | 1999 | 726 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.030 |
Why?
| | Amino Acid Substitution | 2 | 2006 | 304 | 0.030 |
Why?
| | Peptide Mapping | 1 | 2015 | 63 | 0.030 |
Why?
| | Structure-Activity Relationship | 2 | 2006 | 570 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2015 | 224 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2006 | 766 | 0.030 |
Why?
| | Protein Stability | 1 | 2015 | 178 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 627 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 442 | 0.020 |
Why?
| | Imidazoles | 1 | 2015 | 254 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 851 | 0.020 |
Why?
| | Galactosamine | 1 | 2011 | 3 | 0.020 |
Why?
| | Isotope Labeling | 1 | 2012 | 82 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2012 | 144 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2027 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1370 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 824 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 238 | 0.020 |
Why?
| | Endotoxins | 1 | 2011 | 221 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 574 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 277 | 0.020 |
Why?
| | Glutathione | 1 | 2011 | 375 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2011 | 259 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2496 | 0.020 |
Why?
| | Ploidies | 1 | 2007 | 20 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 32 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2007 | 64 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2006 | 73 | 0.020 |
Why?
| | Phenanthrenes | 1 | 2006 | 12 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 1997 | 2194 | 0.010 |
Why?
| | Phenylalanine | 1 | 2006 | 71 | 0.010 |
Why?
| | Neutrophils | 1 | 2011 | 1134 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 612 | 0.010 |
Why?
| | Thermodynamics | 1 | 2006 | 426 | 0.010 |
Why?
| | Aged | 1 | 2023 | 25913 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1833 | 0.010 |
Why?
| | Child | 1 | 2022 | 22633 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5992 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2007 | 928 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2947 | 0.010 |
Why?
| | Disease Progression | 1 | 2007 | 2847 | 0.010 |
Why?
| | Thionucleotides | 1 | 1999 | 35 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 510 | 0.010 |
Why?
| | Hot Temperature | 1 | 1999 | 407 | 0.010 |
Why?
| | Middle Aged | 1 | 2007 | 35875 | 0.000 |
Why?
|
|
Lampe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|